About Isogenica

Isogenica develops VHH, versatile antibodies for bi- and multi- specifics, ADCs, cell and gene therapies.

Excellence in

Single Domain Biotherapeutics

Isogenica develops VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.

VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.

Meet our Team

Our experienced team learned their craft at Ablynx, Bicycle Therapeutics, Roche and other leading biopharma.